PGP and neoplasm: The main pharmacological strategy of preclinical and clinical research to overcome MDR and revert the resistant phenotype is represented by the co-administration of anticancer chemotherapy drug and P-gp substrate-inhibitor compounds in order to restore the effective therapeutic concentration of the drug in the tumor resistant cells [3].